Compound Evidence File
#EC-2026-0600
RAD140
Filed under Oral Tablets. The bureau holds 103 laboratory returns for this compound from 32 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
32 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 11 Dec 2025 | 22 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 19 Nov 2025 | 22 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 21 Feb 2026 | 1 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 10.0 | 10.0 | 11 Dec 2025 | 6 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Feb 2026 | 7 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 3 Jun 2026 | 23 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Mar 2026 | 15 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 13 Jan 2026 | 19 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 12 Feb 2026 | 8 Apr 2026 |
| Hunan GoodPeptides Biotech CoCASE #VI-2026-0370 | X | 1 | 10.0 | 10.0 | 10.0 | 9 Jun 2025 | 9 Jun 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Mar 2026 | 6 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 9.9 | 6 May 2026 | 19 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 15 Apr 2026 | 7 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 27 Apr 2026 | 8 Jul 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 9.5 | 8.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.6 | 7.3 | 10.0 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.5 | 7.8 | 9.7 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.2 | 7.1 | 9.2 | 25 May 2026 | 25 May 2026 |
| CellupepCASE #VI-2026-0888 | X | 1 | 8.2 | 8.2 | 8.2 | 24 Apr 2025 | 24 Apr 2025 |
| EHZ PeptidesCASE #VI-2026-0296 | C | 2 | 8.1 | 7.8 | 8.3 | 6 May 2025 | 23 May 2026 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 8.1 | 8.1 | 8.1 | 7 May 2025 | 7 May 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 7.7 | 7.1 | 9.0 | 23 May 2026 | 23 May 2026 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 7.6 | 7.6 | 7.6 | 8 Jul 2025 | 8 Jul 2025 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 7.5 | 7.5 | 7.5 | 14 Jan 2025 | 14 Jan 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 2 | 7.2 | 6.7 | 7.6 | 3 Jun 2025 | 24 May 2026 |
| Pura PeptidesCASE #VI-2026-0307 | X | 1 | 7.1 | 7.1 | 7.1 | 21 May 2025 | 21 May 2025 |
| HXNetCASE #VI-2026-0061 | X | 8 | 6.8 | 4.9 | 9.4 | 17 Dec 2024 | 19 Jan 2026 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 2 | 6.1 | 5.9 | 6.2 | 14 Jan 2025 | 24 May 2026 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 1 | 4.6 | 4.6 | 4.6 | 6 May 2025 | 6 May 2025 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 3 | 2.8 | 2.1 | 3.3 | 16 Mar 2025 | 25 May 2026 |
Open any subject to view the batch-level evidence for RAD140 alone.